Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgrastim dosing schedules for persistent neutropenia
NCT00770172Phase 3Completed
- Sponsor
- Centre François Baclesse
- Start
- Oct 2007
- Primary completion
- May 2011
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of filgrastim in neutropenia (2 arms), sponsored by Centre François Baclesse. Primary endpoints: Number of courses of G-CSF required and Efficacy in preventing persistent moderate neutropenia. Started Oct 2007; status: completed.
02
Drugs
filgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT00770172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00770172.